Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...
Verywell Health on MSN8h
Trump's Tariffs Are About To Make OTC Medicines Very PriceyThe Trump Administration's 10% tariff on all Chinese imports took effect on Feb. 4. Many unknowns remain, but Americans will ...
New kits are designed to offer a convenient method to label any antibody with one of Bio-Rad’s StarBright Dyes.
Revenue in Q4 2024 increased 45% to $13.53 billion driven by volume growth from Mounjaro and Zepbound. Non-incretin revenue(i) grew by 20% compared to Q4 2023.Pipeline progress included the approval ...
Bristol-Myers Squibb (NYSE:BMY) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback